Literature DB >> 14736233

Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.

Sharada Sivaraman1, Todd J Sullivan, Francis Johnson, Polina Novichenok, Guanglei Cui, Carlos Simmerling, Peter J Tonge.   

Abstract

To explore the molecular basis for the picomolar affinity of triclosan for FabI, the enoyl reductase enzyme from the type II fatty acid biosynthesis pathway in Escherichia coli, an SAR study has been conducted using a series of triclosan analogues. Triclosan (1) is a slow, tight-binding inhibitor of FabI, interacting specifically with the E.NAD(+) form of the enzyme with a K(1) value of 7 pM. In contrast, 2-phenoxyphenol (2) binds with equal affinity to the E.NAD(+) (K(1) = 0.5 microM) and E.NADH (K(2) = 0.4 microM) forms of the enzyme and lacks the slow-binding step observed for triclosan. Thus, removal of the three triclosan chlorine atoms reduces the affinity of the inhibitor for FabI by 70,000-fold and removes the preference for the E.NAD(+) FabI complex. 5-Chloro-2-phenoxyphenol (3) is a slow, tight-binding inhibitor of FabI and binds to the E.NAD(+) form of the enzyme (K(1) = 1.1 pM) 7-fold more tightly than triclosan. Thus, while the two ring B chlorine atoms are not required for FabI inhibition, replacement of the ring A chlorine increases binding affinity by 450,000-fold. Given this remarkable observation, the SAR study was extended to the 5-fluoro-2-phenoxyphenol (4) and 5-methyl-2-phenoxyphenol (5) analogues to further explore the role of the ring A substituent. While both 4 and 5 are slow, tight-binding inhibitors, they bind substantially less tightly to FabI than triclosan. Compound 4 binds to both E.NAD(+) and E.NADH forms of the enzyme with K(1) and K(2) values of 3.2 and 240 nM, respectively, whereas compound 5 binds exclusively to the E.NADH enzyme complex with a K(2) value of 7.2 nM. Thus, the ring A substituent is absolutely required for slow, tight-binding inhibition. In addition, pK(a) measurements coupled with simple electrostatic calculations suggest that the interaction of the ring A substituent with F203 is a major factor in governing the affinity of analogues 3-5 for the FabI complex containing the oxidized form of the cofactor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736233     DOI: 10.1021/jm030182i

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  34 in total

1.  Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.

Authors:  Shahila Mehboob; Kirk E Hevener; Kent Truong; Teuta Boci; Bernard D Santarsiero; Michael E Johnson
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

Review 2.  Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.

Authors:  Pan Pan; Peter J Tonge
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

Review 3.  The reductase steps of the type II fatty acid synthase as antimicrobial targets.

Authors:  Yong-Mei Zhang; Ying-Jie Lu; Charles O Rock
Journal:  Lipids       Date:  2004-11       Impact factor: 1.880

4.  Crystallization and preliminary X-ray crystallographic analysis of enoyl-ACP reductase III (FabL) from Bacillus subtilis.

Authors:  Kook-Han Kim; Joon Kyu Park; Byung Hak Ha; Jin Ho Moon; Eunice EunKyeong Kim
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-02-28

5.  Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents.

Authors:  Julia Fernández de Luco; Alejandro I Recio-Balsells; Diego G Ghiano; Ana Bortolotti; Juán Manuel Belardinelli; Nina Liu; Pascal Hoffmann; Christian Lherbet; Peter J Tonge; Babu Tekwani; Héctor R Morbidoni; Guillermo R Labadie
Journal:  RSC Med Chem       Date:  2020-11-05

6.  Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.

Authors:  Christopher W am Ende; Susan E Knudson; Nina Liu; James Childs; Todd J Sullivan; Melissa Boyne; Hua Xu; Yelizaveta Gegina; Dennis L Knudson; Francis Johnson; Charles A Peloquin; Richard A Slayden; Peter J Tonge
Journal:  Bioorg Med Chem Lett       Date:  2008-04-18       Impact factor: 2.823

7.  Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.

Authors:  Suresh K Tipparaju; Debbie C Mulhearn; Gary M Klein; Yufeng Chen; Subhasish Tapadar; Molly H Bishop; Shuo Yang; Juan Chen; Mahmood Ghassemi; Bernard D Santarsiero; James L Cook; Mary Johlfs; Andrew D Mesecar; Michael E Johnson; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2008-08       Impact factor: 3.466

8.  Uptake and accumulation of antimicrobials, triclocarban and triclosan, by food crops in a hydroponic system.

Authors:  Shiny Mathews; Shannon Henderson; Dawn Reinhold
Journal:  Environ Sci Pollut Res Int       Date:  2014-01-25       Impact factor: 4.223

9.  Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.

Authors:  Hao Lu; Peter J Tonge
Journal:  Biochemistry       Date:  2010-02-16       Impact factor: 3.162

10.  Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.

Authors:  Gustavo A Afanador; Stephen P Muench; Martin McPhillie; Alina Fomovska; Arne Schön; Ying Zhou; Gang Cheng; Jozef Stec; Joel S Freundlich; Hong-Ming Shieh; John W Anderson; David P Jacobus; David A Fidock; Alan P Kozikowski; Colin W Fishwick; David W Rice; Ernesto Freire; Rima McLeod; Sean T Prigge
Journal:  Biochemistry       Date:  2013-12-13       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.